Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 13, 2026

CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP

View original at seekingalpha.com
CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP Earnings Call Insights: CareTrust REIT (CTRE) Q4 2025 MANAGEMENT VIEW * David Sedgwick, CEO, described 2025 as a “transformational year” for CareTrust, highlighting a record pace of investments and the company’s expansion into the U.K…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • With great operators and beefy coverage, CareTrust can manage through any headwinds in skilled nursing

    80% confidence
  • 2026 guidance does not assume any new investments, dispositions, debt repayments, or equity issuances beyond those announced to date

    80% confidence
  • CareTrust doubled its team of professionals in 2025 and brought in-house capabilities like tax and data science

    80% confidence
  • Q4 normalized FFO increased 42.7% year-over-year to $104.1 million and normalized FAD increased 38.7% to $103 million

    80% confidence
  • Investment pipeline remains strong at approximately $500 million

    80% confidence
  • The difference for continued strong growth is that the team is deeper and more capable, and they have the U.K. and SHOP TAMs to play in as well

    80% confidence
  • The $500 million pipeline is about half U.K. care homes, about one-third U.S. skilled nursing, and the rest is a combination of SHOP deal, triple-net seniors and a couple of small loans

    80% confidence
  • The skilled nursing environment is in a really good place right now with labor in a much better place than recent history

    80% confidence
  • SHOP deals are heavily marketed and the company targets a low double-digit IRR

    80% confidence
  • Q4 investments totaled approximately $562 million with a blended stabilized yield of 8.8%

    80% confidence
  • The start of 2026 feels very much like deja vu all over again compared to the beginning of 2025

    80% confidence
  • Most competition is seen in SHOP where cap rates continue to compress as investors seek more exposure

    80% confidence
  • 2025 was a transformational year for CareTrust with record pace of investments and expansion into U.K. care home market and U.S. SHOP

    80% confidence
  • Data analytics team is prioritized on building out SHOP capabilities but will ultimately impact the whole organization

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP — Source | Via News | Via News